Recruiting

Testing a new oral medication for psoriasis safety and how the body responds

Plain-English translation of NCT06846710 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

Read our Psoriasis research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

Researchers are testing a new medication called to see if it is safe and effective for treating psoriasis. The study has two main parts: first, healthy volunteers will take a single dose to check for safety, and second, people with moderate to severe psoriasis will take multiple doses over time. The researchers will watch closely for side effects and measure how the medication moves through the body.

Psoriasis is a chronic skin condition that significantly affects patients' quality of life, and current treatments don't work well enough for everyone. This trial is testing whether this new oral medication could offer a better treatment option.

Do you qualify?

You likely qualify if…

you are between 18 and 45 years old (for the first part with healthy volunteers) or 18 to 65 years old (for the second part with psoriasis patients)
you have had moderate to severe plaque psoriasis for at least 6 months (for the second part only)
you weigh between 45 and 110 kg (about 99 to 242 pounds)
you are in good overall health with normal or non-significant abnormal lab and heart test results (for the first part only)
you are willing to have blood samples taken and safety exams throughout the study

You likely don't qualify if…

you have a history of immune-related diseases or known allergies to the medication or its components
you have used illegal drugs in the past 3 to 5 years or tested positive for drugs
you have had serious infections in the past 2 months or need ongoing antibiotics
you have other types of psoriasis besides plaque psoriasis, such as pustular or erythrodermic psoriasis
you have a history of chronic or recurrent infections affecting your lungs, kidneys, or skin

What participation looks like

If you qualify for the first part, you will take a single oral dose of the medication (or placebo) and have blood samples and safety exams over a short period. If you qualify for the second part, you will take multiple doses of the medication over several weeks or months at one of multiple study centers, with regular blood tests, safety checks, and skin assessments to measure how well the treatment works for your psoriasis.

AI-generated summary from trial data · Jun 14, 2026 · Not medical advice

Trial locations(9 sites)

United States

Kinetic Clinical Research, Anaheim, California

Clinitiative - Floridian Clinical Research, LLC, Miami Lakes, Florida

NuLine Clinical Trial Center (Network), Pompano Beach, Florida

New Zealand

Pacific Clinical Research Network (PCRN), Auckland, Takapuna, Auckland

Pacific Clinical Research Network (PCRN), Christchurch, Christchurch, Christchurch